Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab Long-Term Extension in Rheumatoid Arthritis
NCT01146652Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2010
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 40
01
Overview
Phase 3, open-label trial of sarilumab in rheumatoid arthritis (RA) (2 arms), sponsored by Sanofi. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) up to 523 weeks and Number of Participants Reported Product Technical Complaints (PTC), Product Technical Failures (PTF) and/or Failed Drug Deliveries (FDD). Started Jun 2010; status: completed.
02
Drugs
sarilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01146652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01146652.